Quest Diagnostics Reports Second Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026
Quest Diagnostics (NYSE: DGX) reported Q2 2026 revenues of $3.04B, up 10.2% year over year, with 10.0% organic growth. Diluted EPS was $2.84 (+15.0%); adjusted diluted EPS was $3.12 (+19.1%). Full-year 2026 guidance raised to $11.95B-$12.05B revenue and reported diluted EPS $9.97-$10.17, adjusted $11.05-$11.25.
How this was made
The 30-second read
Why it matters
The key tradable items are the raised full-year revenue and EPS ranges, supported by Q2 outperformance and an adjusted effective tax rate expectation consistent with 2025.
Market read
A guidance raise with specific numeric ranges is a direct catalyst for earnings-estimate revisions and positioning ahead of the earnings call.
What to watch
The release highlights multiple initiatives and partnerships, but it does not quantify margin or cash-flow impacts in the provided text, which could temper the stock reaction.
Background
Quest Diagnostics issued its Q2 2026 earnings release and updated full-year 2026 guidance, citing strong organic growth and favorable tax contingency resolution.
Ticker impact
Quest Diagnostics reported Q2 2026 revenue of $3.04B and raised full-year 2026 revenue and EPS guidance ranges.
Likely positive bias for DGX around the earnings call, with follow-through if guidance is viewed as credible versus Street expectations.
The release provides specific Q2 results and explicit updated full-year 2026 revenue, GAAP EPS, and adjusted EPS ranges, plus a stated driver for tax-related guidance.
Market effects
Positive read-through for US clinical diagnostics lab operators if investors extrapolate demand and pricing power.
Primarily US healthcare services sentiment; limited direct regional spillover beyond healthcare equities.
Low global relevance, as the guidance and operations described are US-focused.
Counterpoint
Guidance raise may be partially offset by non-GAAP adjustments and tax contingency resolution, so investors may scrutinize sustainability of organic growth.
Key entities
- companyQuest Diagnostics Incorporated
US clinical diagnostics provider reporting Q2 2026 results and raising full-year 2026 guidance.
- partnerCorewell Health
Mentioned as a joint venture laboratory collaboration in Michigan.
- partnerFresenius Medical Care
Mentioned for kidney care collaboration capabilities.
- technology_partnerFlatiron Health
Mentioned for OncoEMR Molecular Profiling Integration platform used for select cancer tests.
